Regulatory clearances, especially for early-stage trials, are critical milestones for biotech companies. Such news often leads to positive investor sentiment as it represents progress in the company's pipeline. Given the specificity of the clearance for a novel radiopharmaceutical, this is likely to be viewed positively by the market, driving short-term interest and potentially increasing the stock price.